Mindset announces a drug development agreement with Japanese-based Otsuka Pharmaceuticals, including a $5 million strategic investment in Mindset.
Mindset announces a drug development agreement with Japanese-based Otsuka Pharmaceuticals, including a $5 million strategic investment in Mindset.
After a tough year for stock performance in 2021, we lay out why the psychedelic drug industry is poised to bounce back strongly in 2022.
The Military Mental Health Crisis affects over 1 million veterans and has claimed 115,000+ lives in the past 20 years. Fortunately, there is finally hope.
MindMed announces that the FDA has placed "clinical hold" on its initial IND submission in preparation for its Phase 2b clinical trial for generalized anxiety disorder (GAD).
Novamind announces a definitive agreement to acquire Arizona-based Foundations for Change, PLC.
In Part II, we take a personal look at the journey into PTSD Hell. We also examine the additional serious issues facing veterans attempting to cope with PTSD.
Mydecine announces an LOI to co-develop its own digital therapeutics platform, in partnership with Maya Health.
Cybin Inc provides a year-end update highlighting drug and IP development as well as international expansion.
Optimi Health receives its Health Canada Dealers' License and initiates new Quality Assurance Department.
2021 was two different "years" for the psychedelic drug industry. Impressive progress in drug R&D and clinics; stocks pushed down to absurdly lean multiples.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now